The number of people living with neurological disorders, such as Alzheimer’s disease, epilepsy, multiple sclerosis and Parkinson’s disease, has increased as the population has aged. At the same time, ...

Lecanemab reduces toxic amyloid-β protofibrils, slowing Alzheimer’s disease progression and supporting personalised treatment ...

The disease afflicts nearly seven million Americans, about one in every nine people over the age of 65, making it a leading ...

LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies.

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Researchers uncover promising evidence that xenon gas, commonly used in anesthesia, may help reduce brain deterioration and ...